Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions
Running, not enrolling · Phase 1
Conditions studied: Head and Neck Cancer
In brief
To characterize the safety and tolerability of nivolumab injected intralesionally in patients with high-risk oral premalignant lesions.
Key facts
- Study ID
- NCT05327270
- Run by
- M.D. Anderson Cancer Center
- People needed
- 18
- Starts
- 2022-09-13
- Expected to finish
- 2027-02-02
- Last updated by the study team
- 2026-06-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- M D Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.